EPAR summary for the public
This document is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to
Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific D cu sion (also part of the EPAR).
- Ristaben - Merck Sharp
Popisanih lijekova na recept. Proizvođač: "Merck Sharp "
Trevaclyn is a medicine containing two active substances: nicotinic acid (also known as niacin or vitamin B3) and laropiprant. It is available as
hypercholesterolaemia’. Patients with combined mixed dyslipidaemia have high blood levels of ‘bad’ LDL cholesterol and triglycerides (a type of fat), and low levels of ‘good’ HDL cholesterol. Primary hypercholesterolaemia is when the levels of cholesterol in the blood are high. Primary means that the hypercholesterolaemia does not have any identifiable cause.
The medicine can only be obtained with a prescription.
Trevaclyn is normally given together with a statin (the standard medicine used to reduce cholesterol) when the effectivenessMedicinalof a st tin taken alone is inadequate. Trevaclyn is used on its own only in patients who cannot take stati s.
How is Trevaclyn us d?